The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis

被引：8
|
作者：
Long, Jianting [1 ]
Fang, Shi [2 ]
Dai, Qiangsheng [1 ]
Liu, Xiaolian [3 ]
Zhu, Wanshou [3 ]
Wang, Shenming [4 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med Oncol, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Clin Nutr, Guangzhou 510080, Guangdong, Peoples R China
[3] Gaozhou Peoples Hosp, Dept Hematol, Gaozhou 525200, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc Surg, Guangzhou 510080, Guangdong, Peoples R China
来源：
ONCOTARGET | 2016年 / 7卷 / 22期
基金：
中国国家自然科学基金; 国家教育部博士点专项基金资助;
关键词：
acute myeloid leukemia; Wilms' tumor gene 1; association; meta-analysis; SINGLE-NUCLEOTIDE POLYMORPHISM; EXPRESSION; GENE; DIFFERENTIATION; PREDICTS; CANCER;
D O I：
10.18632/oncotarget.8117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Although a number of studies suggested that WT1 rs16754 polymorphism might be related to decreased relapse free survival (RFS) and overall survival (OS). The results remain controversial. Published reports were searched in PubMed, EMBASE, and Google Scholar. Twelve publications with 3903 patients had met the inclusion criteria and were subjected to further examination. We found WT1 rs16754 polymorphism was significantly associated with OS in AML (OR = 0.62; 95% CI 0.52 - 0.75; p < 0.00001; I-2 = 47%). WT1 rs16754 polymorphism was also significantly associated with RFS in AML (OR = 0.69; 95% CI 0.57 - 0.83; p < 0.001; I-2 = 46%). In the subgroup analyses of age, race, and subtype of AML, WT1 rs16754 polymorphism was a independent favorable-risk marker. In conclusion, WT1 rs16754 polymorphism is associated with better survival of AML. It could be used as a cost-effective prognostic biomarker for AML.
引用
收藏
页码：32079 / 32087
页数：9
相关论文
共 50 条
  • [41] The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG)
    Ho, Phoenix A.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Kuhn, Julia
    Pollard, Jessica A.
    Hirsch, Betsy A.
    Raimondi, Susana C.
    Gamis, Alan S.
    Meshinchi, Soheil
    BLOOD, 2011, 118 (21) : 628 - 628
  • [42] A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
    Niavarani, Ahmadreza
    Herold, Tobias
    Reyal, Yasmin
    Sauerland, Maria C.
    Buchner, Thomas
    Hiddemann, Wolfgang
    Bohlander, Stefan K.
    Valk, Peter J. M.
    Bonnet, Dominique
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (03) : 401 - 411
  • [43] Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia
    Awada, Hassan
    Durmaz, Arda
    Gurnari, Carmelo
    Kishtagari, Ashwin
    Zawit, Misam
    Pagliuca, Simona
    Visconte, Valeria
    BLOOD CELLS MOLECULES AND DISEASES, 2021, 88
  • [44] The Prognostic Effect of High Diagnostic WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: Report From the Children's Oncology Group
    Ho, Phoenix A.
    Alonzo, Todd A.
    Gerbing, Robert B.
    Kuhn, Julia
    Pollard, Jessica A.
    Hirsch, Betsy
    Raimondi, Susana C.
    Gamis, Alan S.
    Meshinchi, Soheil
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 81 - 88
  • [45] A Prospective Study to Evaluate the Prognostic Implications of Methylation and Expression of Wilms Tumor-1 (WT-1) Gene in Acute Myeloid Leukemia
    Goel, Harsh
    Chopra, Anita
    Ranjan, Amar
    Meena, Jagdish Prasad
    Gupta, Aditya Kumar
    Viswanathan, Ganesh Kumar
    Bakhshi, Sameer
    Khan, Maroof Ahmad
    Tanwar, Pranay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S284 - S285
  • [46] WT1 And DNMT3A Mutations in Prognostic Significance of Acute Myeloid Leukemia: A Meta-Analysis
    Ma, Shiyue
    Tang, Lingjian
    Tang, Hui
    Wu, Chaoli
    Pu, Xue
    Yang, Jun
    Niu, Ninhong
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024,
  • [47] EXPLORING WILMS TUMOR GENE (WT1) IN ACUTE MYELOID LEUKEMIA - INITIAL EXPERIENCES
    Rejto, L.
    Biro, S.
    Vargha, G.
    Ujj, Zs
    Batar, P.
    Szasz, R.
    Telek, B.
    Kiss, A.
    Remenyi, Gy
    Mehes, L.
    Udvardy, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 554 - 554
  • [48] Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia
    Barragán, E
    Cervera, J
    Bolufer, P
    Ballester, S
    Martín, G
    Fernández, P
    Collado, R
    Sayas, MJ
    Sanz, MA
    HAEMATOLOGICA, 2004, 89 (08) : 926 - 933
  • [49] Pilot trial of a Wilms tumor-1 (WT1) peptide vaccine in patients with thoracic and myeloid neoplasms
    Brown, A. B.
    Krug, L. M.
    Maslak, P.
    James, L. P.
    Dao, T.
    Tyson, L.
    Chanel, S. M.
    Bekele, S.
    Scheinberg, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Immune dominant Wilms' Tumor 1 (WT1) peptides as target structure for cellular immune therapy in acute myeloid leukemia (AML)
    Buttkereit, U.
    Hermann, E.
    Ottinger, H.
    Beelen, D. W.
    ONKOLOGIE, 2012, 35 : 58 - 58
12345